Oruka Therapeutics (ORKA) Cash from Investing Activities Growth (1y) (2011 - 2026)
Powered by 
Analysis
Oruka Therapeutics (ORKA) Cash from Investing Activities Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 90.55% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.53% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -41.67% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -157.08% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 26.37% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -89.24% |
| 10 | Oruka Therapeutics | 5.85 Bn | 4.12 Bn | - | -8,555.70% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -8,555.70% |
| Mar 31, 2026 | -133.68% |
| Dec 31, 2025 | 93.33% |
| Sep 30, 2025 | -71,507.60% |
| Mar 31, 2022 | 66.67% |
| Dec 31, 2021 | 46.15% |
| Jun 30, 2021 | -433.33% |
| Mar 31, 2021 | -100.00% |
| Dec 31, 2020 | -550.00% |
| Sep 30, 2018 | 99.68% |
| Mar 31, 2018 | 1.36% |
| Dec 31, 2017 | 50.86% |
| Sep 30, 2017 | 63.42% |
| Jun 30, 2017 | 151.65% |
| Mar 31, 2017 | 157.82% |
| Dec 31, 2016 | 157,500.00% |
| Sep 30, 2016 | -127,300.00% |
| Jun 30, 2016 | -236,140.00% |
| Mar 31, 2016 | -260,000.00% |
| Dec 31, 2015 | 85.71% |